MYOMO INC

Company Overview

Myomo Inc. is a wearable medical robotics company (Healthcare; Medical Devices) that develops the MyoPro family of myoelectric upper-limb orthoses to restore or amplify voluntary movement for patients with neuromuscular disorders and partial paralysis. The business is concentrated: Motion G drove ~98% of 2024 revenue, the company holds a portfolio of patents through 2042, and commercial progress is tightly coupled to reimbursement (Medicare Part B reclassification and new CMS fee levels materially improved economics). Sales mix is shifting to direct billing (≈77–78% of product revenue in 2024–Q2 2025), backlog and prior-authorization timing drive revenue recognition, and manufacturing combines contract electromechanical kits with in‑house final fabrication at a recently expanded Burlington, MA facility. Management is scaling headcount, R&D and clinical/reimbursement capabilities while remaining dependent on payer decisions and access to capital.

Executive Compensation Practices

Given Myomo’s stage and business drivers, executive pay is likely structured to emphasize variable, performance-based incentives tied to revenue growth, ASP/margin improvement, direct-billing conversion, backlog conversion/prior-authorization throughput, and cash/Adjusted EBITDA targets rather than solely GAAP profit. Long-term incentives are probably equity-heavy (options/RSUs) to conserve cash while aligning executives with stock appreciation tied to reimbursement wins, product rollouts (e.g., MyoPro 2X, future MyoPro3/MyoPal) and patent/clinical milestones. R&D and regulatory milestones (FDA/MDR compliance, clinical study outcomes) and manufacturing ramp metrics are natural non-financial KPIs for bonuses or milestone vesting, while retention awards are likely used as the company hires >100 staff. Board and compensation committees will also weigh dilution concerns and investor sentiment after recent equity financings when setting pay levels.

Insider Trading Considerations

Insiders at Myomo will often trade around clearly material events for a reimbursement‑dependent Medical Devices company: CMS/HCPCS determinations, payer coverage updates, backlog/prior‑authorization disclosures, product launches, clinical outcomes, and financing announcements (e.g., Dec 2024 equity raise). Expect heightened volatility around quarterly results and CMS payment changes, and watch for clustered insider sales following equity grants, financing dilution, or improved cash runway disclosures; conversely, opportunistic buys may occur after positive reimbursement rulings. Regulatory constraints — Section 16 reporting, short‑swing profit rules, blackout periods, preclearance policies, and the practical need to avoid trading on nonpublic payer or audit information — are important; many insiders will use 10b5‑1 plans or formal trading windows to manage compliance. For traders and researchers, insider filings tied to reimbursement milestones and delivery/backlog conversions will often be the most informative signals for near‑term company trajectory.